ArticleScientific reports2026
Pharmacogenetics of RAS-affecting AGT and ACE variants and the efficacy of Valsartan/HCTZ therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Considerable inter-individual variability has been observed in the blood pressure response to valsartan/hydrochlorothiazide (Valsartan/HCTZ), and genetic differences within the renin-angiotensin system may contribute to this heterogeneity. This prospective cohort study included 354 hypertensive patients treated with Valsartan/HCTZ (80/12.5 mg or 160/12.5 mg). Baseline and 4-week BP measurements were recorded following standardized procedures, and five variants (AGT rs5050, rs5051, rs699, rs4762, and ACE I/D) were genotyped using PCR-based methods. Associations were evaluated through linear and multivariate regression, and multilocus interactions were examined using estimated marginal means. Overall, the cohort showed reductions of 23.2 ± 16.4 mmHg in SBP and 14.8 ± 10.9 mmHg in DBP. Among clinical factors, normal BMI was associated with greater reductions (22.9 ± 15.9; 15.5 ± 9.3 mmHg) compared with BMI ≥ 35 kg/m² (14.2 ± 17.3; 10.7 ± 11.4 mmHg). Hypertension-specific diets produced larger SBP decreases (25.6 ± 17.6 mmHg) than unrestricted diets (22.9 ± 16.3 mmHg). Increasing dose had only a modest additional effect. AGT rs5050 showed the strongest genetic association, with SBP decreasing by 26 mmHg in CA/CC carriers versus 13.4 mmHg in AA (p < 0.001). ACE I/D significantly affected DBP, with II carriers achieving 13.7 mmHg versus 8.0 mmHg in DD (p = 0.017). A significant AGT rs5050 × ACE I/D interaction revealed the greatest reduction in AC/II (20.6 ± 2.3 mmHg) and the lowest in AA/DD (3.80 ± 2.33 mmHg). These findings highlight meaningful multilocus effects and support the potential for genotype-guided antihypertensive therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.